journal
Journals American Journal of Clinical D...

American Journal of Clinical Dermatology

https://read.qxmd.com/read/38767827/the-use-of-biologic-agents-for-the-treatment-of-cutaneous-immune-related-adverse-events-from-immune-checkpoint-inhibitors-a-review-of-reported-cases
#1
REVIEW
Jolanta Pach, Kailyn Valido, Annika Belzer, Jonathan S Leventhal
Cutaneous immune-related adverse events encompass a spectrum of dermatological manifestations, including lichenoid reactions, psoriasiform eruptions, eczematous dermatitis, immunobullous disorders, granulomatous reactions, pruritus, vitiligo, and severe cutaneous adverse reactions such as Stevens-Johnson syndrome. The conventional approach to treating high-grade or refractory cutaneous immune-related adverse events has involved high-dose systemic corticosteroids. However, their use is limited owing to the potential disruption of antitumor responses and associated complications...
May 20, 2024: American Journal of Clinical Dermatology
https://read.qxmd.com/read/38755503/management-and-long-term-outcomes-of-drug-reaction-with-eosinophilia-and-systemic-symptoms-dress-in-children-a-scoping-review
#2
REVIEW
Nicole Cherepacha, Frances St George-Hyslop, Bindiya Chugani, Yousef Alabdeen, Luis F Sanchez-Espino, Quenby Mahood, Cathryn Sibbald, Ruud H J Verstegen
Drug reaction with eosinophilia and systemic symptoms (DReSS) is known to cause mortality and long-term sequelae in the pediatric population, however there are no established clinical practice guidelines for the management of pediatric DReSS. We conducted a scoping review, according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, to summarize the currently available data on treatment, mortality, and long-term sequelae of DReSS in children (aged 0-18 years). Data from 644 individuals revealed that various treatment strategies are being used in the management of pediatric DReSS, and strategies were often used in combination...
May 16, 2024: American Journal of Clinical Dermatology
https://read.qxmd.com/read/38748391/managing-the-patient-with-psoriasis-and-metabolic-comorbidities
#3
REVIEW
Francesco Bellinato, Martina Maurelli, Davide Geat, Giampiero Girolomoni, Paolo Gisondi
Epidemiological data demonstrate strong associations between psoriasis and metabolic comorbidities, including obesity, hypertension, diabetes mellitus, dyslipidemia, and non-alcoholic fatty liver disease. The presence of metabolic comorbidities significantly influences the selection and effectiveness of pharmacological treatments. Some drugs should be prescribed with caution in patients with metabolic comorbidities because of an increased risk of adverse events, while others could have a reduced effectiveness...
May 15, 2024: American Journal of Clinical Dermatology
https://read.qxmd.com/read/38744780/approach-to-the-atypical-wound
#4
REVIEW
Sarah L Becker, Shannon Kody, Nicole M Fett, Alexander Hines, Afsaneh Alavi, Alex G Ortega-Loayza
The heterogeneity of atypical wounds can present diagnostic and therapeutic challenges; however, as the prevalence of atypical wounds grows worldwide, prompt and accurate management is increasingly an essential skill for dermatologists. Addressing the underlying cause of an atypical wound is critical for successful outcomes. An integrated approach with a focus on pain management and patient engagement is recommended to facilitate enduring wound closure. Advances in treatment, in addition to further research and clinical training, are necessary to address the expanding burden of atypical wounds...
May 14, 2024: American Journal of Clinical Dermatology
https://read.qxmd.com/read/38743155/dupilumab-safety-and-efficacy-up-to-1-year-in-children-aged-6-months-to-5-years-with-atopic-dermatitis-results-from-a-phase-3-open-label-extension-study
#5
JOURNAL ARTICLE
Amy S Paller, Elaine C Siegfried, Eric L Simpson, Michael J Cork, Robert Sidbury, Iris H Chen, Faisal A Khokhar, Jing Xiao, Ariane Dubost-Brama, Ashish Bansal
BACKGROUND: Pediatric patients with moderate-to-severe atopic dermatitis (AD) often experience a high disease burden and have a high risk of persistent disease. Standard-of-care immunosuppressive systemic treatments have been used off-label for AD in pediatric patients despite concerns for suboptimal safety with continuous use and risk of relapse upon discontinuation. The biologic agent dupilumab is the first systemic treatment approved for moderate-to-severe AD in children as young as 6 months...
May 14, 2024: American Journal of Clinical Dermatology
https://read.qxmd.com/read/38698175/efficacy-safety-and-long-term-disease-control-of-ruxolitinib-cream-among-adolescents-with-atopic-dermatitis-pooled-results-from-two-randomized-phase-3-studies
#6
JOURNAL ARTICLE
Lawrence F Eichenfield, Eric L Simpson, Kim Papp, Jacek C Szepietowski, Andrew Blauvelt, Leon Kircik, Jonathan I Silverberg, Elaine C Siegfried, Michael E Kuligowski, May E Venturanza, Howard Kallender, Haobo Ren, Amy S Paller
BACKGROUND: Atopic dermatitis (AD), a highly pruritic, inflammatory skin disease, affects approximately 7% of adolescents globally. A topical formulation of ruxolitinib, a Janus kinase (JAK) 1/JAK2 inhibitor, demonstrated safety and efficacy among adolescents/adults in two phase 3 studies (TRuE-AD1/TRuE-AD2). OBJECTIVE: To describe safety and efficacy of 1.5% ruxolitinib cream versus vehicle and long-term disease control of ruxolitinib cream among adolescents aged 12-17 years from pooled phase 3 study data...
May 2, 2024: American Journal of Clinical Dermatology
https://read.qxmd.com/read/38668825/american-academy-of-dermatology-annual-meeting-san-diego-ca-usa-8-12-march-2024
#7
JOURNAL ARTICLE
Kathy A Fraser
No abstract text is available yet for this article.
April 26, 2024: American Journal of Clinical Dermatology
https://read.qxmd.com/read/38649621/merkel-cell-carcinoma-integrating-epidemiology-immunology-and-therapeutic-updates
#8
REVIEW
Jürgen C Becker, Andreas Stang, David Schrama, Selma Ugurel
Merkel cell carcinoma (MCC) is a rare skin cancer characterized by neuroendocrine differentiation. Its carcinogenesis is based either on the integration of the Merkel cell polyomavirus or on ultraviolet (UV) mutagenesis, both of which lead to high immunogenicity either through the expression of viral proteins or neoantigens. Despite this immunogenicity resulting from viral or UV-associated carcinogenesis, it exhibits highly aggressive behavior. However, owing to the rarity of MCC and the lack of epidemiologic registries with detailed clinical data, there is some uncertainty regarding the spontaneous course of the disease...
April 22, 2024: American Journal of Clinical Dermatology
https://read.qxmd.com/read/38635019/ultrasound-surveillance-in-melanoma-management-bridging-diagnostic-promise-with-real-world-adherence-a-systematic-review-and-meta-analysis
#9
Zhao Feng Liu, Amy Sylivris, Johnny Wu, Darren Tan, Samuel Hong, Lawrence Lin, Michael Wang, Christopher Chew
BACKGROUND: Ultrasound surveillance has become the new standard of care in stage III melanoma after the 2017 Multicenter Selective Lymphadenectomy Trial II (MSLT-II) demonstrated non-inferior 3-year survival compared with complete lymph node dissection. OBJECTIVE: We aimed to quantify diagnostic performance and adherence rates of ultrasound surveillance for melanoma locoregional metastasis, offering insights into real-world applicability. METHODS: Conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines, we systematically searched the Medline, Embase, Cochrane Library, CINAHL, Scopus, and Web of Science databases from inception until 11 October 2023...
April 18, 2024: American Journal of Clinical Dermatology
https://read.qxmd.com/read/38578398/secondary-bacterial-infections-in-patients-with-atopic-dermatitis-or-other-common-dermatoses
#10
JOURNAL ARTICLE
Romain Salle, Pascal Del Giudice, Charbel Skayem, Camille Hua, Olivier Chosidow
Secondary bacterial infections of common dermatoses such as atopic dermatitis, ectoparasitosis, and varicella zoster virus infections are frequent, with Staphylococcus aureus and Streptococcus pyogenes being the bacteria most involved. There are also Gram-negative infections secondary to common dermatoses such as foot dyshidrotic eczema and tinea pedis. Factors favoring secondary bacterial infections in atopic dermatitis, ectoparasitosis, and varicella zoster virus infections mainly include an epidermal barrier alteration as well as itch...
April 5, 2024: American Journal of Clinical Dermatology
https://read.qxmd.com/read/38528257/early-and-sustained-improvements-in-symptoms-and-quality-of-life-with-upadacitinib-in-adults-and-adolescents-with-moderate-to-severe-atopic-dermatitis-52-week-results-from-two-phase-iii-randomized-clinical-trials-measure-up-1-and-measure%C3%A2-up%C3%A2-2
#11
JOURNAL ARTICLE
Jonathan I Silverberg, Melinda J Gooderham, Amy S Paller, Mette Deleuran, Christopher G Bunick, Linda F Stein Gold, DirkJan Hijnen, Brian M Calimlim, Wan-Ju Lee, Henrique D Teixeira, Xiaofei Hu, Shiyu Zhang, Yang Yang, Ayman Grada, Andrew M Platt, Diamant Thaçi
BACKGROUND: Atopic dermatitis is a chronic inflammatory disease characterized by increased itch, skin pain, poor sleep quality, and other symptoms that negatively affect patient quality of life. Upadacitinib, an oral selective Janus kinase (JAK) inhibitor with greater inhibitory potency for JAK1 than JAK2, JAK3, or tyrosine kinase 2, is approved to treat moderate-to-severe atopic dermatitis. OBJECTIVE: We aimed to evaluate the effect of upadacitinib on patient-reported outcomes over 52 weeks in adults and adolescents with moderate-to-severe atopic dermatitis...
March 25, 2024: American Journal of Clinical Dermatology
https://read.qxmd.com/read/38498268/tree-based-machine-learning-to-identify-predictors-of-psoriasis-incidence-at-the-neighborhood-level-a-populational-study-from-quebec-canada
#12
JOURNAL ARTICLE
Anastasiya Muntyanu, Raymond Milan, Mohammed Kaouache, Julien Ringuet, Wayne Gulliver, Irina Pivneva, Jimmy Royer, Max Leroux, Kathleen Chen, Qiuyan Yu, Ivan V Litvinov, Christopher E M Griffiths, Darren M Ashcroft, Elham Rahme, Elena Netchiporouk
BACKGROUND: Psoriasis is a major global health burden affecting ~ 60 million people worldwide. Existing studies on psoriasis focused on individual-level health behaviors (e.g. diet, alcohol consumption, smoking, exercise) and characteristics as drivers of psoriasis risk. However, it is increasingly recognized that health behavior arises in the context of larger social, cultural, economic and environmental determinants of health. We aimed to identify the top risk factors that significantly impact the incidence of psoriasis at the neighborhood level using populational data from the province of Quebec (Canada) and advanced tree-based machine learning (ML) techniques...
March 18, 2024: American Journal of Clinical Dermatology
https://read.qxmd.com/read/38494575/expert-panel-review-of-skin-and-hair-dermatophytoses-in-an-era-of-antifungal-resistance
#13
REVIEW
Rachel C Hill, Avrom S Caplan, Boni Elewski, Jeremy A W Gold, Shawn R Lockhart, Dallas J Smith, Shari R Lipner
Dermatophytoses are fungal infections of the skin, hair, and nails that affect approximately 25% of the global population. Occlusive clothing, living in a hot humid environment, poor hygiene, proximity to animals, and crowded living conditions are important risk factors. Dermatophyte infections are named for the anatomic area they infect, and include tinea corporis, cruris, capitis, barbae, faciei, pedis, and manuum. Tinea incognito describes steroid-modified tinea. In some patients, especially those who are immunosuppressed or who have a history of corticosteroid use, dermatophyte infections may spread to involve extensive skin areas, and, in rare cases, may extend to the dermis and hair follicle...
March 18, 2024: American Journal of Clinical Dermatology
https://read.qxmd.com/read/38438782/small-molecule-inhibitors-and-biologics-for-palmoplantar-psoriasis-and-palmoplantar-pustulosis-a-systematic-review-and-network-meta-analysis
#14
JOURNAL ARTICLE
I-Hsin Huang, Po-Chien Wu, Hsien-Yi Chiu, Yu-Huei Huang
BACKGROUND: The comparative efficacy of biologics and small-molecule inhibitors in treating palmoplantar psoriasis (PP) and palmoplantar pustulosis (PPP) remains uncertain. OBJECTIVE: The aim was to perform a systematic review and network meta-analysis (NMA) to compare the efficacy of biologics and small-molecule inhibitors for the treatment of PP and PPP. METHODS: MEDLINE, Embase, and Cochrane Central Register of Controlled Trials were searched for eligible studies from inception to May 13, 2023...
March 4, 2024: American Journal of Clinical Dermatology
https://read.qxmd.com/read/38453786/management-of-acne-in-pregnancy
#15
REVIEW
Akash Rau, Jonette Keri, Jenny E Murase
Acne is one of the most common dermatological conditions to affect women of childbearing age, so it is important to consider the safety of long-term acne treatments on women who could become pregnant. In this review article, we clarify what management options are available to treat acne during pregnancy. Topical treatments, typically first-line for acne, such as azelaic acid, clindamycin, erythromycin, metronidazole, benzoyl peroxide, salicylic acid, dapsone, and retinoids, were reviewed. Systemic treatments, such as zinc supplements, cephalexin, cefadroxil, amoxicillin, azithromycin, erythromycin, and corticosteroids, typically second-line for acne, were also reviewed...
May 2024: American Journal of Clinical Dermatology
https://read.qxmd.com/read/38409643/rapidly-evolving-pre-and-post-surgical-systemic-treatment-of-melanoma
#16
REVIEW
Ryan C Augustin, Jason J Luke
With the development of effective BRAF-targeted and immune-checkpoint immunotherapies for metastatic melanoma, clinical trials are moving these treatments into earlier adjuvant and perioperative settings. BRAF-targeted therapy is a standard of care in resected stage III-IV melanoma, while anti-programmed death-1 (PD1) immunotherapy is now a standard of care option in resected stage IIB through IV disease. With both modalities, recurrence-free survival and distant-metastasis-free survival are improved by a relative 35-50%, yet no improvement in overall survival has been demonstrated...
May 2024: American Journal of Clinical Dermatology
https://read.qxmd.com/read/38351246/field-cancerization-therapies-for-the-management-of-actinic-keratosis-an-updated-review
#17
REVIEW
Ishita Aggarwal, Carolina Puyana, Neha Chandan, Nathan Jetter, Maria Tsoukas
Field cancerization theory highlights that the skin surrounding actinic keratoses (AK) is also at increased risk for possible malignant transformation; thus, field-directed treatments may both reduce the risk of AK recurrence and potentially reduce the risk of development of cutaneous squamous cell carcinoma (cSCC). Photodynamic therapy (PDT) with either aminolevulinic acid (ALA) or methylaminolevulinate (MAL), as well as topical treatments such as 5-fluorouracil (5-FU), diclofenac gel, piroxicam, imiquimod, and ingenol mebutate, have all shown higher efficacy than vehicle treatments...
May 2024: American Journal of Clinical Dermatology
https://read.qxmd.com/read/38305944/autoimmune-and-cutaneous-inflammatory-comorbidities-in-adult-onset-morphea-in-the-all-of-us-research-program
#18
LETTER
Jill T Shah, William Mark Richardson, Lavanya Mittal, Emily Hejazi, Daniel R Mazori, Alisa N Femia
No abstract text is available yet for this article.
March 2024: American Journal of Clinical Dermatology
https://read.qxmd.com/read/38265746/treatment-of-psoriasis-patients-with-latent-tuberculosis-using-il-17-and-il-23-inhibitors-a-retrospective-multinational-multicentre-study
#19
MULTICENTER STUDY
Tiago Torres, Andrea Chiricozzi, Luis Puig, Ana Maria Lé, Angelo Valerio Marzano, Paolo Dapavo, Esteban Dauden, Jόse-Manuel Carrascosa, Elizabeth Lazaridou, Gleison Duarte, André V E Carvalho, Ricardo Romiti, Natalia Rompoti, Laetitia Teixeira, Miguel Abreu, Elena Ippoliti, Carlo Alberto Maronese, Mar Llamas-Velasco, Eva Vilarrasa, Elena Del Alcázar, Athina-Ioanna Daponte, Marina Papoutsaki, Andrea Carugno, Francesco Bellinato, Paolo Gisondi
BACKGROUND: Tuberculosis has a major global impact. Immunocompetent hosts usually control this disease, resulting in an asymptomatic latent tuberculosis infection (LTBI). Because TNF inhibitors increase the risk of tuberculosis reactivation, current guidelines recommend tuberculosis screening before starting any biologic drug, and chemoprophylaxis if LTBI is diagnosed. Available evidence from clinical trials and real-world studies suggests that IL-17 and IL-23 inhibitors do not increase the risk of tuberculosis reactivation...
March 2024: American Journal of Clinical Dermatology
https://read.qxmd.com/read/38263353/integrated-safety-analysis-of-ritlecitinib-an-oral-jak3-tec-family-kinase-inhibitor-for-the-treatment-of-alopecia-areata-from-the-allegro-clinical-trial-program
#20
JOURNAL ARTICLE
Brett King, Jennifer Soung, Christos Tziotzios, Lidia Rudnicka, Pascal Joly, Melinda Gooderham, Rodney Sinclair, Natasha A Mesinkovska, Carle Paul, Yankun Gong, Susan D Anway, Helen Tran, Robert Wolk, Samuel H Zwillich, Alexandre Lejeune
BACKGROUND: The ALLEGRO phase 2a and 2b/3 studies demonstrated that ritlecitinib, an oral JAK3/TEC family kinase inhibitor, is efficacious at doses of ≥ 30 mg in patients aged ≥ 12 years with alopecia areata (AA). OBJECTIVE: The objective of this study was to evaluate the safety of ritlecitinib in an integrated analysis of four studies in AA. METHODS: Two cohorts were analyzed: a placebo-controlled and an all-exposure cohort...
March 2024: American Journal of Clinical Dermatology
journal
journal
34795
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.